Studies are ongoing to better define the role of exogenous cytokines in vaccine design and development. For these and other ongoing studies, several transgenic (Tg) mouse strains have been developed for vaccine therapy tumor models. These include Tg mice that express either CEA or MUC-1 as self-antigens at sites similar to those expressed in humans, and two Tg mouse strains that develop spontaneous tumors. Double Tg mouse strains have recently been developed in which spontaneous tumors arise that express either CEA or MUC-1 as self-antigen and in tumor tissue. Preclinical and clinical studies have now demonstrated the role of GM-CSF in vaccine therapy by recruitment of dendritic cells. Recombinant avipox viruses have now been developed that express GM-CSF as a transgene. When administered as a single injection, these vectors have recently been shown to enhance both the percentage and absolute number of APC (including dendritic cells) in the regional lymph nodes that drain the injection site. Both the magnitude and duration of this response was shown to be far greater than that achieved with the administration of four daily injections of recombinant GM-CSF protein. Recent studies have shown that the co-administration of recombinant avipox virus expressing CEA with recombinant avipox virus expressing GM-CSF significantly enhanced CEA-specific immunity, with an accompanying immunotherapeutic response in tumor-bearing CEA Tg mice. Studies are ongoing to use the new transgenic tumor models to better define novel vaccine strategies.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010428-03
Application #
6763844
Study Section
(LTIB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Yang, Sixun; Tsang, Kwong-Yok; Schlom, Jeffrey (2005) Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res 11:5603-15
Reali, E; Canter, D; Zeytin, H et al. (2005) Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 23:2909-21
Hodge, James W; Chakraborty, Mala; Kudo-Saito, Chie et al. (2005) Multiple costimulatory modalities enhance CTL avidity. J Immunol 174:5994-6004
Zeytin, Hasan E; Patel, Arti C; Rogers, Connie J et al. (2004) Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res 64:3668-78
Palena, Claudia; Arlen, Philip; Zeytin, Hasan et al. (2003) Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. Cytokine 24:128-42